Neurocrine falls 29% on Phase IIb tardive dyskinesia miss
This article was originally published in Scrip
Neurocrine Biosciences fell 29% in after-hours trading on 9 September after the company said its 50mg dose of NBI-98854 for the treatment of tardive dyskinesia missed the six-week primary endpoint in a Phase IIb clinical trial, but a 100mg dose provided statistically significant improvements without worsening patients' schizophrenia after just two weeks of therapy.
You may also be interested in...
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.